SAT0239 Rapid response with upadacitinib treatment in patients with rheumatoid arthritis and an inadequate response to csdmards or bdmards
Authors: O. FitzGerald, A. Rubbert-Roth, K. Chen, S. Meerwein, J. Enejosa, T. Shaw, A. F. Wells
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients (pts) with moderate to severe rheumatoid arthritis (RA) with an inadequate response (IR) to csDMARDs or bDMARDs in the SELECT-NEXT<sup>1</sup> and SELECT-BEYOND<sup>2</sup> trials, respectively. <h3>Objectives:</h3> To investigate the speed of response to UPA across disease measures in csDMARD- and bDMARD-IR pts. <h3>Methods:</h3> 661 pts in NEXT and 498 in BEYOND received UPA 15 mg or UPA 30 mg once daily (QD) or placebo (PBO) for 12 weeks (wks)<sup>1,2</sup>. Time to first achievement of clinically meaningful outcomes, including ACR20/50, DAS28-CRP≤3.2 and Low Disease Activity (LDA) measures of CDAI (≤10) and SDAI (≤11) was evaluated. The cumulative incidences of ACR20/50, DAS28-CRP≤3.2 and LDA by CDAI and SDAI over 12 wks were estimated. Hazard ratios between UPA and PBO were obtained using Cox proportional hazards model with treatment group, corresponding baseline values and main stratification factors, without control for multiple comparisons. All analyses were based on observed data without imputation. <h3>Results:</h3> Pts had a disease duration of 7 and 13 years in NEXT and BEYOND respectively.<sup>1,2</sup> In BEYOND, pts were treatment-refractory as evidenced by 53% having received ≥2 prior bDMARDs<sup>2</sup>. Median times to achieve ACR20 were similar, irrespective of pt population, being 4 wks for UPA 15 mg QD and 2–3 wks for UPA 30 mg QD vs 12 wks on PBO (p&lt;0.001). In general, the median times to achieve ACR50 and DAS28-CRP≤3.2 for UPA 15 mg and 30 mg QD were ~12 wks and ~8 wks for both csDMARD-IR and bDMARD-IR pts, whereas the median was not reached for pts on PBO during the first 12 wks (p&lt;0.001, table 1). The median time to LDA by CDAI and SDAI was ~12 wks across UPA doses and populations, but was not reached for pts receiving PBO within that time. Pts receiving UPA were 2–4 times more likely to achieve clinical responses vs pts receiving PBO. In general, both UPA doses performed similarly across pt populations, with numerically quicker responses observed in pts receiving UPA 30 mg vs UPA 15 mg QD. Median times to achieve 20% and 50% improvements in tender and swollen joint counts were 1–2 wks and 2–4 wks respectively, for both UPA doses, irrespective of pt population. Median times to achieve 20% improvements in morning stiffness duration and severity were approximately 2 wks in each of the UPA arms vs 4 wks on PBO (p&lt;0.001). <h3>Conclusions:</h3> Pts receiving UPA at either 15 mg or 30 mg QD were more likely to achieve clinical responses at significantly earlier time points when compared with pts receiving PBO. Irrespective of being csDMARD-IR or bDMARD-IR, times to achieve various clinical responses were consistent between pt populations. <h3>References</h3> [1]Burmester, et al. Arthritis Rheumatol2017;69S10. [2]Genovese, et al. Arthritis Rheumatol2017;69S10. <h3>Acknowledgements:</h3> AbbVie: Study sponsor, study design, data collection, analysis &amp; interpretation, writing, review, approval of final. Medical writing:Naina Barretto of AbbVie <h3>Disclosure of Interest:</h3> O. FitzGerald Grant/research support from: Pfizer, Abbvie, Lilly, Celgene, Novartis, BMS and Janssen, Speakers bureau: Pfizer, Abbvie, Lilly, Celgene, Novartis, BMS and Janssen, A. Rubbert-Roth Consultant for: Abbvie, BMS, Chugai, Pfizer, Roche, Janssen, Lilly, Sanofi, Amgen, Novartis, Speakers bureau: Abbvie, BMS, Chugai, Pfizer, Roche, Janssen, Lilly, Sanofi, Amgen, Novartis, K. Chen Shareholder of: AbbVie, Employee of: AbbVie, S. Meerwein Shareholder of: AbbVie, Employee of: AbbVie, J. Enejosa Shareholder of: AbbVie, Employee of: AbbVie, T. Shaw Shareholder of: AbbVie, Employee of: AbbVie, A. Wells Grant/research support from: AbbVie, Consultant for: AbbVie